68Ga-PSMA PET/CT in Prostate Cancer

Summary

The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PET/CT and as a diagnostic and decision making tool in the management prostate cancer patients.The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 7 days following the scan, and the sensitivity and specificity of 68Ga-PSMA PET/CT vs CT on a per-patient and per-lesion basis.

Timeline

Start

2017-07-01

Primary completion

2023-07-01

Completion

2023-07-01

Drugs

Indications